Another interesting article (for a number of reasons) surrounding the current climate of the US pharma market/FDA approval pathway, specifically GlaxoSmithKline's new myeloma fighting drug."The US Food and Drug Administration (FDA) has fast-tracked GSK’s antibody-drug conjugate (ADC) belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma. GSK filed the drug back inDecemberafter the drug demonstrated positive results in clinical trials.
The priority review was based on the positive results from a second pivotal trial of the ADC –DREAMM2 – which revealed a 31% overall response rate (ORR) for those receiving the drug who had exhausted multiple previous treatment options for multiple myeloma."
Underlined for effect. Sounds pretty familiar...
Edit: Forgot the link: https://www.pmlive.com/pharma_news/fda_fast-tracks_gsks_anti-bcma_drug_for_multiple_myeloma_1323112
-
- There are more pages in this discussion • 10,310 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
0.015(1.22%) |
Mkt cap ! $215.4M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.23 | $106.2K | 85.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 11900 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 819 | 1 |
View Market Depth
| Last trade - 15.56pm 26/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |